27655998|t|Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease
27655998|a|von Willebrand factor (VWF) is a biomarker for endothelial damage. Increased VWF levels are observed in hypertension (HTN) and disorders of endothelial dysfunction, for example, atherosclerotic heart disease (ASHD) and diabetes. Whether low VWF protects against HTN is unknown. To determine prevalence and risk factors for HTN in patients with von Willebrand disease (VWD), we conducted a cross-sectional analysis of discharge data from the National Inpatient Sample, 2009 to 2011. Group comparisons were performed by Rao-Scott χ(2) test. Odds of HTN and HTN outcomes in VWD were estimated by weighted multivariable logistic regression. The prevalence of hypertension in patients with VWD (N = 7556), 37.35%, was significantly lower than that in non-VWD patients (N = 19 918 970), 49.40%, P < .0001. Hypertension risk factors (hyperlipidemia, diabetes, smoking, hepatitis C, and HIV) and HTN outcomes (ASHD, myocardial infarction [MI], ischemic stroke, and renal failure) were less common in patients with VWD than in non-VWD patients, all P ≤ .0001. Patients with VWD were younger, 49.67 versus 57.30 years, Caucasian, 82.23% versus 68.35%, and female, 75.44% versus 59.61%, P < .0001. Patients with HTN were older, 67.55 versus 47.29 years, male, 45.99% versus 34.90%, and had more HTN risk factors and HTN outcomes than those without HTN, all P < .0001, including male and female subgroups, each P < .0001. The unadjusted odds of HTN in patients with VWD (odds ratio [OR] = 0.611, P < .0001) and of HTN outcomes in patients with VWD (ASHD, OR = 0.509; MI, OR = 0.422; ischemic stroke, OR = 0.521; renal failure, OR = 0.420, all P < .0001) became insignificant after adjustment for HTN risk factors plus demographics (age / race / gender), OR = 1.035, P = .260. The risk of HTN is reduced in patients with VWD, but not after adjustment for HTN risk factors plus demographics, as patients with VWD not having HTN are also typically young, Caucasian, and female.
27655998	15	27	Risk Factors	T033	UMLS:C0035648
27655998	44	56	Hypertension	T038	UMLS:C0020538
27655998	60	82	von Willebrand Disease	T038	UMLS:C0042974
27655998	83	104	von Willebrand factor	T103	UMLS:C0042971
27655998	106	109	VWF	T103	UMLS:C0042971
27655998	116	125	biomarker	T201	UMLS:C0005516
27655998	130	141	endothelial	T017	UMLS:C0014257
27655998	142	148	damage	T037	UMLS:C0010957
27655998	160	163	VWF	T103	UMLS:C0042971
27655998	187	199	hypertension	T038	UMLS:C0020538
27655998	201	204	HTN	T038	UMLS:C0020538
27655998	223	246	endothelial dysfunction	T038	UMLS:C0856169
27655998	261	290	atherosclerotic heart disease	T038	UMLS:C0010054
27655998	292	296	ASHD	T038	UMLS:C0010054
27655998	302	310	diabetes	T038	UMLS:C0011847
27655998	324	327	VWF	T103	UMLS:C0042971
27655998	345	348	HTN	T038	UMLS:C0020538
27655998	389	401	risk factors	T033	UMLS:C0035648
27655998	406	409	HTN	T038	UMLS:C0020538
27655998	427	449	von Willebrand disease	T038	UMLS:C0042974
27655998	451	454	VWD	T038	UMLS:C0042974
27655998	472	496	cross-sectional analysis	T062	UMLS:C0010362
27655998	601	620	Rao-Scott χ(2) test	T170	UMLS:C0008041
27655998	630	633	HTN	T038	UMLS:C0020538
27655998	638	641	HTN	T038	UMLS:C0020538
27655998	654	657	VWD	T038	UMLS:C0042974
27655998	685	718	multivariable logistic regression	T062	UMLS:C0206031
27655998	738	750	hypertension	T038	UMLS:C0020538
27655998	768	771	VWD	T038	UMLS:C0042974
27655998	829	836	non-VWD	T033	UMLS:C0243095
27655998	883	895	Hypertension	T038	UMLS:C0020538
27655998	896	908	risk factors	T033	UMLS:C0035648
27655998	910	924	hyperlipidemia	T038	UMLS:C0020473
27655998	926	934	diabetes	T038	UMLS:C0011847
27655998	945	956	hepatitis C	T038	UMLS:C0019196
27655998	962	965	HIV	T038	UMLS:C0019693
27655998	971	974	HTN	T038	UMLS:C0020538
27655998	985	989	ASHD	T038	UMLS:C0010054
27655998	991	1012	myocardial infarction	T038	UMLS:C0027051
27655998	1014	1016	MI	T038	UMLS:C0027051
27655998	1019	1034	ischemic stroke	T038	UMLS:C0948008
27655998	1040	1053	renal failure	T038	UMLS:C0035078
27655998	1089	1092	VWD	T038	UMLS:C0042974
27655998	1101	1108	non-VWD	T033	UMLS:C0243095
27655998	1148	1151	VWD	T038	UMLS:C0042974
27655998	1192	1201	Caucasian	T098	UMLS:C0043157
27655998	1284	1287	HTN	T038	UMLS:C0020538
27655998	1367	1370	HTN	T038	UMLS:C0020538
27655998	1371	1383	risk factors	T033	UMLS:C0035648
27655998	1388	1391	HTN	T038	UMLS:C0020538
27655998	1420	1423	HTN	T038	UMLS:C0020538
27655998	1466	1475	subgroups	T170	UMLS:C1515021
27655998	1516	1519	HTN	T038	UMLS:C0020538
27655998	1537	1540	VWD	T038	UMLS:C0042974
27655998	1585	1588	HTN	T038	UMLS:C0020538
27655998	1615	1618	VWD	T038	UMLS:C0042974
27655998	1620	1624	ASHD	T038	UMLS:C0010054
27655998	1638	1640	MI	T038	UMLS:C0027051
27655998	1654	1669	ischemic stroke	T038	UMLS:C0948008
27655998	1683	1696	renal failure	T038	UMLS:C0035078
27655998	1767	1770	HTN	T038	UMLS:C0020538
27655998	1771	1783	risk factors	T033	UMLS:C0035648
27655998	1809	1813	race	T098	UMLS:C0034510
27655998	1859	1862	HTN	T038	UMLS:C0020538
27655998	1891	1894	VWD	T038	UMLS:C0042974
27655998	1925	1928	HTN	T038	UMLS:C0020538
27655998	1929	1941	risk factors	T033	UMLS:C0035648
27655998	1978	1981	VWD	T038	UMLS:C0042974
27655998	1993	1996	HTN	T038	UMLS:C0020538
27655998	2023	2032	Caucasian	T098	UMLS:C0043157